Generic Combination Products May Be Permitted Delivery Device Variations
Executive Summary
But US FDA officials say brand vs. generic product differences won't be appropriate in all cases and patient misuse remains a concern.
You may also be interested in...
How Star Wars Explains Biosimilar Labeling Problems
US FDA largely writes biosimilar labels that are the same as their reference products even though it’s not required, which could hinder product development and uptake, experts say.
Growing Complex Generic Application Load May Force US FDA Staffing Changes
Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.
Growing Complex Generic Application Load May Force US FDA Staffing Changes
Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.